Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CryoCor files against CryoCath in regulation patent dispute

This article was originally published in Clinica

Executive Summary

CryoCor and CryoCath, competitors in the cardiac arrhythmia market, are now locked in a rivalry in court. CryoCor has filed two patent infringement lawsuits against CryoCath, one in the US district court of Delaware and one filed in Canada, claiming that the latter's products infringe patents relating to its cardiac cryoablation system. San Diego, California-based CryoCor is seeking monetary damages and injunctions to prohibit CryoCath from selling its products in the US and Canada. The action comes as a countersuit against a previous claim made by CryoCath (Montreal, Canada) in October 2007, alleging that CryoCor had infringed on patents covering CryoCath's console technology. Both companies specialise in manufacturing minimally invasive catheter systems designed to treat cardiac arrhythmias with the use of cryoablation.

You may also be interested in...

Finance Watch: Biopharma VC Explosion Extends To Tools, Services

Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.

Zimmer Biomet Buys Sternal Closure Company A&E Medical

The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.

Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts